Ardelyx Stock Price, News & Analysis

Ardelyx (NASDAQ:ARDX) reported strong Q2 2025 financial results, with total revenue of $97.7 million, representing a 33% year-over-year growth. The company's flagship products showed significant performance: IBSRELA generated $65.0 million in net sales (84% YoY growth) and XPHOZAH contributed $25.0 million.

Key financial highlights include a strong cash position of $238.5 million as of June 30, 2025. The company raised its 2025 IBSRELA revenue guidance to $250-$260 million. Despite revenue growth, Ardelyx reported a net loss of $19.1 million ($0.08 per share) for Q2 2025.

Notable developments include securing an option to draw additional debt of $100 million through SLR Investment Corp. and key executive appointments including Mike Kelliher as Chief Business Officer and James P. Brady as Chief Human Resources Officer.

Ardelyx (NASDAQ:ARDX), a biopharmaceutical company focused on developing first-in-class medicines, has scheduled its second quarter 2025 financial results conference call for August 4, 2025, at 4:30 p.m. Eastern Time.

The company will discuss Q2 2025 financial performance and provide business updates. Investors can join via phone at (877) 346-6112 (domestic) or (848) 280-6350 (international). A live webcast will be available on the Investors section of www.ardelyx.com and archived for 30 days after the call.

Ardelyx (ARDX) has announced key leadership changes with Mike Kelliher's promotion to Chief Business Officer and James P. Brady's appointment as Chief Human Resources Officer. Kelliher, who joined in March 2024 as EVP of Corporate Development and Strategy, will now oversee lifecycle and portfolio management alongside his existing responsibilities. His background includes significant experience at Horizon Therapeutics, where he played a key role in growth initiatives and acquisitions. Brady joins from Spero Therapeutics, where he served as CHRO and helped earn Best Places to Work recognition. He brings extensive HR experience from roles at uniQure, Intarcia Therapeutics, and Genzyme Corporation. These appointments align with Ardelyx's strategy to strengthen its leadership team for continued growth and value creation.

Ardelyx (NASDAQ: ARDX), a biopharmaceutical company focused on developing first-in-class medicines for unmet medical needs, has announced its participation in the upcoming Jefferies Global Healthcare Conference 2025. President and CEO Mike Raab will engage in a fireside chat on June 4, 2025, at 8:10 am ET in New York. The presentation will be accessible via live webcast on the company's website, with a replay available for 30 days following the event.

Ardelyx (ARDX) presented data supporting IBSRELA® (tenapanor), their FDA-approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, at the Digestive Disease Week Conference. Key findings include:

The IBS in America 2024 survey revealed that higher IBS-C symptom severity correlates with increased financial hardship. The analysis used FACIT-COST® and PROMIS® scales to assess financial toxicity and symptoms.

Safety data from the Phase 3 R-ALLY study in pediatric patients (12-18 years) with IBS-C showed no serious adverse events, with diarrhea being the only drug-related side effect. Additionally, a Phase 1 study demonstrated that tenapanor was not detectable in breast milk of healthy lactating females after repeated administration.

Ardelyx (ARDX) reported strong Q1 2025 financial results with total revenue of $74.1 million, representing 61% growth year-over-year. Key highlights include IBSRELA net product sales of $44.4 million (57% YoY growth) and XPHOZAH net product sales of $23.4 million. The company maintained a solid financial position with $214.0 million in cash and investments. IBSRELA's full-year 2025 revenue guidance remains between $240-250 million. Notable developments include tenapanor's approval in China for hyperphosphatemia, earning a $5.0 million milestone payment from Fosun Pharma. However, the company reported a net loss of $41.1 million ($0.17 per share) for Q1 2025, compared to $26.5 million loss in Q1 2024, primarily due to increased commercialization costs.

Ardelyx has strengthened its board of directors with the appointment of Merdad Parsey, M.D., Ph.D., a veteran biotech leader with over 25 years of pharmaceutical industry experience. Parsey, who recently retired as Chief Medical Officer at Gilead Sciences in 2025, brings extensive expertise in clinical development and leadership.

His impressive career includes key positions at prominent organizations:

• Chief Medical Officer at Gilead Sciences (2019-2025)
• Senior Vice President of early clinical development at Genentech (2015-2019)
• CEO of 3-V Biosciences (2010-2015)

Parsey's appointment aligns with Ardelyx's mission to develop first-in-class medicines for unmet medical needs. His background in research, early development, and clinical strategy positions him to support the company's growth objectives, including expanding their commercial products and building a robust medicine pipeline.

Ardelyx (Nasdaq: ARDX) has announced the acceptance of three abstracts for poster presentations at the Digestive Disease Week Conference (DDW) in San Diego, May 3-6, 2025. The presentations will showcase data on IBSRELA® (tenapanor), their FDA-approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults.

The three poster presentations will cover:

• Safety and tolerability of tenapanor in pediatric IBS-C patients
• A pharmacokinetic study of tenapanor in breast milk of healthy lactating females
• Correlation between IBS-C symptom severity and financial burden from the IBS in America 2024 survey

Additionally, Ardelyx will sponsor a Product Theater on May 4, featuring Dr. Satish Rao and Christina Hanson, NP, discussing clinical considerations for managing adult IBS-C patients, including efficacy and safety data from Phase 3 trials.

Ardelyx (NASDAQ: ARDX) has scheduled its first quarter 2025 financial results conference call for Thursday, May 1, 2025, at 4:30 p.m. Eastern Time. The biopharmaceutical company will discuss Q1 2025 financial performance and provide a business update during the call.

Investors can participate by dialing (877) 346-6112 (domestic) or (848) 280-6350 (international). A live audio webcast will be available on the Investors section of Ardelyx's website at www.ardelyx.com, with a 30-day replay period following the call.